Candriam S.C.A. Iovance Biotherapeutics, Inc. Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

A detailed history of Candriam S.C.A. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 500,033 shares of IOVA stock, worth $3.92 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

500,033

Previous 500,033 -0.0%

Holding current value

$3.92 Million

Previous $4.01 Million 17.08%

% of portfolio

0.03%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$7.78 - $14.19 $4.35 Million - $7.93 Million	-559,109 Reduced 52.79%	500,033 $4.01 Million
Q1 2024 May 03, 2024	SELL	$7.59 - $17.47 $5.08 Million - $11.7 Million	-668,680 Reduced 38.7%	1,059,142 $15.7 Million
Q4 2023 Feb 14, 2024	SELL	$3.3 - $8.89 $3.37 Million - $9.07 Million	-1,020,031 Reduced 37.12%	1,727,822 $14 Million
Q3 2023 Nov 13, 2023	BUY	$4.44 - $8.79 $4.53 Million - $8.97 Million	1,020,037 Added 59.04%	2,747,853 $12.5 Million
Q2 2023 Aug 08, 2023	BUY	$5.36 - $9.06 $181,682 - $307,097	33,896 Added 2.0%	1,727,816 $12.2 Million
Q1 2023 May 12, 2023	BUY	$5.53 - $8.22 $774,200 - $1.15 Million	140,000 Added 9.01%	1,693,920 $10.3 Million
Q4 2022 Feb 13, 2023	SELL	$5.62 - $10.0 $646,300 - $1.15 Million	-115,000 Reduced 6.89%	1,553,920 $9.93 Million
Q3 2022 Nov 10, 2022	BUY	$9.53 - $13.11 $381,200 - $524,400	40,000 Added 2.46%	1,668,920 $16 Million
Q2 2022 Aug 03, 2022	BUY	$6.38 - $18.33 $3.04 Million - $8.73 Million	476,335 Added 41.33%	1,628,920 $18 Million
Q1 2022 May 13, 2022	BUY	$12.38 - $19.1 $3.17 Million - $4.89 Million	256,221 Added 28.58%	1,152,585 $19.2 Million
Q4 2021 Feb 10, 2022	BUY	$16.55 - $27.63 $789,633 - $1.32 Million	47,712 Added 5.62%	896,364 $17.1 Million
Q3 2021 Nov 09, 2021	SELL	$20.35 - $26.63 $3.5 Million - $4.57 Million	-171,774 Reduced 16.83%	848,652 $20.9 Million
Q2 2021 Jul 20, 2021	BUY	$16.33 - $33.07 $7 Million - $14.2 Million	428,376 Added 72.35%	1,020,426 $26.6 Million
Q1 2021 Apr 29, 2021	SELL	$28.67 - $52.59 $344 - $631	-12 Reduced -0.0%	592,050 $26.4 Million
Q4 2020 Jan 22, 2021	SELL	$28.04 - $50.26 $2.61 Million - $4.68 Million	-93,019 Reduced 13.58%	592,062 $27.5 Million
Q3 2020 Oct 19, 2020	SELL	$27.75 - $36.3 $2.01 Million - $2.63 Million	-72,575 Reduced 9.58%	685,081 $22.6 Million
Q2 2020 Jul 23, 2020	BUY	$27.21 - $41.0 $15.9 Million - $24 Million	584,152 Added 336.68%	757,656 $20.8 Million
Q1 2020 May 26, 2020	BUY	$19.54 - $38.85 $508 - $1,010	26 Added 0.01%	173,504 $4.7 Million
Q4 2019 Jan 21, 2020	BUY	$17.95 - $29.41 $1.87 Million - $3.06 Million	103,978 Added 149.61%	173,478 $5,000
Q3 2019 Oct 21, 2019	BUY	$17.99 - $26.0 $386,784 - $559,000	21,500 Added 44.79%	69,500 $1,000
Q2 2019 Aug 01, 2019	BUY	$9.78 - $24.52 $469,439 - $1.18 Million	48,000 New	48,000 $1.17 Million
Q3 2018 Nov 07, 2018	SELL	$11.25 - $17.7 $1.26 Million - $1.98 Million	-112,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$12.45 - $16.95 $186,750 - $254,250	15,000 Added 15.46%	112,000 $1.43 Million
Q1 2018 May 09, 2018	BUY	$8.1 - $19.5 $785,700 - $1.89 Million	97,000 New	97,000 $1.64 Million

Others Institutions Holding IOVA

# of Institutions

314

Shares Held

241M

Call Options Held

3.77M

Put Options Held

1.7M

View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.24B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

More about IOVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account